20 October 2025 Global Medical Technologies Global Medtech: The Long View on China... slides and transcript from our webinar Lisa Bedell Clive +44 207 676 7256 lisa.clive@bernsteinsg.com Susannah Ludwig +41 582 723 127 susannah.ludwig@bernsteinsg.com Delphine Le Louet +33 1 42 13 92 93 delphine.le-louet@bernsteinsg.com Lee Hambright +1 917 344 8429 lee.hambright@bernsteinsg.com Estelle Pang +44 207 676 7646 estelle.pang@bernsteinsg.com Richard Hombach +44 207 762 1858 richard.hombach@bernsteinsg.com Deeksha ...

Key Takeaways Zimmer Biomet will report third-quarter 2025 results on Nov. 5 before market open. ZBH's revenues are estimated at $2.01B, up 10.2% year over year, with EPS expected to rise 8.1%. ZBH's growth in hips, knees, and S.E.T. units, plus new product approvals, may boost quarterly results. Zimmer Biomet Holdings, Inc. (ZBH) is scheduled to report third-quarter 2025 results on Nov. 5, before market open.In the last reported quarter, the company’s earnings of $2.07 surpassed the Zacks Consensus Estimat ...

Core Insights - Zimmer Biomet Holdings, Inc. is showcasing its innovations in robotics and musculoskeletal solutions at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS) [1][2] - The company emphasizes the urgency for advanced orthopedic solutions due to an aging population and rising patient expectations for less disruption and faster recovery [3] Product Highlights - The mBôsâ™ TKA System is a CT-based, semi-autonomous robotic technology for total knee arthroplasty that has received FDA 510(k) clearance, with a fully autonomous version in clinical trials [7] - The ROSA Knee with OptimiZe™ is the latest version of the ROSA Knee System, pending FDA clearance, designed to enhance surgical planning and accuracy [7] - The TMINI Miniature Robotic System is a handheld, wireless CT-based robotic system for precise implant placement [7] - ZBEdge Analytics provides intra-operative insights via a smartphone application, allowing surgeons to assess performance and clinical decisions [7] - The mymobility Care Management Platform offers continuous data and patient feedback to improve surgical preparation and recovery [7] - The Oxford Cementless Partial Knee is the only FDA-approved mobile cementless partial knee implant in the U.S., known for its efficiency and survivorship [7] - The Persona OsseoTi Keel Tibia is a cementless tibia for TKA featuring a 3D printed porous tray for stable fixation [7] - The Persona® SoluTion™ PPS® Femur is designed for patients with metal sensitivities, featuring a porous coating for cementless fixation [7] - Persona IQ The Smart Knee captures patient-specific metrics for post-operative insights, enhancing the TKA patient experience [7] Strategic Vision - The company aims to lead in orthopedic innovation by integrating robotics, digital platforms, and AI to improve surgical precision and patient outcomes [3][9] - Zimmer Biomet's commitment to innovation is highlighted as the most ambitious cycle in its history, positioning it to deliver comprehensive orthopedic solutions [3]

Zimmer Biomet Holdings Inc. (NYSE:ZBH) ranks among the best medical device stocks to invest in. Zimmer Biomet Holdings Inc. (NYSE:ZBH) announced on October 7 that it successfully acquired Monogram Technologies Inc., an AI-driven orthopedic robotics firm, for an upfront payment of about $177 million. This expands Zimmer Biomet’s orthopedic solution range by integrating Monogram’s semi-autonomous and fully autonomous robotic technology. Source: Pixabay Zimmer Biomet’s technology portfolio already includes ...

With a market cap of $18.8 billion, Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company that designs, manufactures, and markets innovative orthopedic reconstructive products, sports medicine solutions, biologics, and surgical technologies. The company serves healthcare professionals worldwide with advanced products that treat disorders and injuries of bones, joints, and soft tissues. The Warsaw, Indiana-based company is slated to announce its fiscal Q3 2025 results before the market ...

Core Insights - Zimmer Biomet Holdings (NYSE: ZBH) has experienced a challenging stock performance over the past month, recording single-digit losses, similar to the losses observed in 2025 [1] Company Performance - The stock has faced single-digit losses recently, indicating a tough market environment for the company [1] Analyst Background - Gamu Dave Innocent Pasi, a financial professional with extensive experience in investment research, has a strong background in analyzing financial statements and capital markets [1] - He is recognized for providing actionable trading ideas and well-researched investment recommendations, contributing to reputable publications [1] - Pasi holds a Postgraduate Executive Certificate in Investments and Portfolio Management and a Bachelor of Business Studies Honors degree in Banking and Finance [1] Investment Philosophy - Pasi is passionate about innovative solutions that promote financial inclusion, sustainability, and measurable social impact [1] - He advocates for Responsible Investment and actively incorporates Environmental, Social, and Governance (ESG) principles in investment decision-making [1]

Company Developments - Zimmer Biomet Holdings (ZBH) and its subsidiary Paragon 28 have launched two solutions for complex foot and ankle trauma: the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail, enhancing the company's trauma portfolio [1][9] - The Gorilla Pilon Fusion Plating System addresses primary tibiotalar fusion for patients with pilon fractures, which represent approximately 7% to 10% of all tibial fractures [4][5] - The Phantom TTC Trauma Nail expands on the existing Phantom TTC Nail platform, offering enhanced lengths and fixation capabilities for complex trauma cases [7][10] Financial Performance - Following the announcement of the new products, ZBH shares decreased by 0.7%, closing at $98.36 [2] - ZBH has a market capitalization of $19.48 billion and an earnings yield of 8.3%, significantly higher than the industry average of 0.1% [3] Market Outlook - The global foot and ankle device market was valued at $4.76 billion in 2024 and is projected to grow at a compound annual growth rate of 7.1% through 2030, driven by the increasing adoption of minimally invasive treatments and the rising prevalence of conditions like osteoporosis [11] Recent Acquisitions - Zimmer Biomet has completed the acquisition of Monogram Technologies, an AI-driven orthopedic robotics company, which enhances its suite of orthopedic robotics solutions [12] Stock Performance - Over the past three months, ZBH shares have increased by 3.8%, outperforming the industry growth of 0.2% [13]

从这里开始写正文 文章来源：骨未来 转载要求：可以直接转载，请在文首注明来源 全关节置换术后感染（PJI）的临床挑战 全关节置换术（如髋关节和膝关节置换）是治疗晚期关节疾病的标准方法，全球每年进行数百万例手术。然 而，PJI作为一种严重并发症，影响约1-2%的初次置换患者，在翻修手术中发生率可升至5-10%。PJI通常由细 菌（如金黄色葡萄球菌或铜绿假单胞菌）在植入物表面形成生物膜引发，导致慢性感染难以根治。 临床上，PJI患者可能面临败血症、关节功能丧失甚至截肢的风险。今年发表的研究显示，髋关节PJI的死亡率 与乳腺癌相当，凸显其对患者生命的威胁。此外，PJI还带来沉重的经济负担：单次治疗平均成本在发达国家 可达5万至10万美元，包括多次手术、抗生素治疗和长期康复。传统防控措施依赖抗生素，但耐药菌株（如耐 甲氧西林金黄色葡萄球菌，MRSA）的兴起使这些方法效果受限，感染复发率高企。全球老龄化趋势进一步放 大这一问题，预计到2030年，关节置换手术需求将增长30%以上，PJI的防控已成为骨科领域的紧迫课题。 碘涂层技术：原理与抗感染机制 2025年9月26日，捷迈邦美Zimmer Biomet（纽交所代码：Z ...

, /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who ...

Core Insights - Zimmer Biomet Holdings, Inc. (ZBH) received approval from the Pharmaceutical and Medical Devices Agency (PMDA) in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology, which inhibits bacterial adhesion on the implant surface [1][10] - The approval enhances ZBH's infection management portfolio, which includes prevention, detection, primary, and revision products [1][10] Product Significance - The iTaperloc and iG7 systems combine the clinical heritage of the Taperloc Complete Hip System with the performance of the G7 Acetabular System, enhanced by Iodine Technology [2] - Implant-associated bacterial infection, or Periprosthetic Joint Infection (PJI), is a significant complication in total joint arthroplasty (TJA), occurring in an estimated 1-2% of primary TJA procedures [3] - The mortality rate associated with PJI is comparable to that of breast cancer, highlighting the critical need for effective solutions [4] Iodine Technology - Iodine is a biocompatible nutrient that does not contribute to antibiotic resistance and is used in medicine as an antiseptic [5] - The application of Iodine Technology during manufacturing inhibits biofilm formation on the implant surface [5] Market Outlook - The global orthopedic implants market is projected to reach $32.47 billion by 2030, growing at a CAGR of 3.78% from 2025 to 2030, driven by increasing prevalence of musculoskeletal disorders [6] Strategic Developments - Zimmer Biomet has agreed to acquire Monogram Technologies Inc., an orthopedic robotics company, for an upfront payment of $4.04 per share, totaling approximately $177 million in equity value [7] - The acquisition aims to enhance ZBH's ROSA Robotics platform with new capabilities from Monogram's semi and fully autonomous robotic technologies, expected to be completed by the end of 2025 [8]